Lu Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lu Deng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cai-Xia Li
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China
1 shared publication - Gang Wang
National Engineering Research Center for Biomaterial, Sichuan University, Chengdu 610065, China
1 shared publication Lifang Xie
National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China
1 shared publicationMing Liu
Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610044, China
1 shared publicationPing Yang
National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China
1 shared publicationWanling Lu
National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2023
- Published by KEAI Publishing in Genes & Diseases
- Vol. 10 (3) , 1101-1113
Prolonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue
Daily insulin injection is necessary for the treatment of the insulin-dependent diabetes. However, the process is painful and inconvenient. Accordingly, we have made exploratory efforts to establish an alternative method for continuous insulin supply via intramuscular injection of a designed plasmid encoding the single-strand insulin analogue (SIA), which provides safe, effective and prolonged control of insulin-dependent diabetes. To generate a SIA, a short flexible peptide was alternatively introduced into the natural proinsulin to replace its original long and rigid C-peptide. Then, the synthetic promoter SP301 was used to drive potent and specific expression of SIA in skeletal muscle cells. By combining the Pluronic L64 and low-voltage electropulse (L/E), the specialized gene delivery technique was applied to efficiently transfer the constructed plasmid into skeletal muscle cells via intramuscular injection. Through these efforts, a plasmid-based intramuscular gene expression system was established and improved, making it applicable for gene therapy. The plasmid-expressed SIA showed biological functions that were similar to that of natural insulin. A single L/E-pSP301-SIA administration provided sustained SIA expression in vivo for about 1.5 months. In addition, the diabetic mice treated with L/E-pSP301-SIA were much healthier than those with other treatments. This plasmid-based system was safe for the treatment of diabetes and did not cause immune responses or pathological damage. The results confirmed that, in a mouse model, long-term positive effects were achieved by a single intramuscular L/E-pSP301-SIA injection, which consequently provided reliable experimental basis for its clinical application for the treatment of diabetes mellitus with promising prospects.
- 1 May 2023
- Published by KEAI Publishing in Genes & Diseases
- Vol. 10 (3) , 1101-1113
Open AccessProlonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue
Daily insulin injection is necessary for the treatment of the insulin-dependent diabetes. However, the process is painful and inconvenient. Accordingly, we have made exploratory efforts to establish an alternative method for continuous insulin supply via intramuscular injection of a designed plasmid encoding the single-strand insulin analogue (SIA), which provides safe, effective and prolonged control of insulin-dependent diabetes. To generate a SIA, a short flexible peptide was alternatively introduced into the natural proinsulin to replace its original long and rigid C-peptide. Then, the synthetic promoter SP301 was used to drive potent and specific expression of SIA in skeletal muscle cells. By combining the Pluronic L64 and low-voltage electropulse (L/E), the specialized gene delivery technique was applied to efficiently transfer the constructed plasmid into skeletal muscle cells via intramuscular injection. Through these efforts, a plasmid-based intramuscular gene expression system was established and improved, making it applicable for gene therapy. The plasmid-expressed SIA showed biological functions that were similar to that of natural insulin. A single L/E-pSP301-SIA administration provided sustained SIA expression in vivo for about 1.5 months. In addition, the diabetic mice treated with L/E-pSP301-SIA were much healthier than those with other treatments. This plasmid-based system was safe for the treatment of diabetes and did not cause immune responses or pathological damage. The results confirmed that, in a mouse model, long-term positive effects were achieved by a single intramuscular L/E-pSP301-SIA injection, which consequently provided reliable experimental basis for its clinical application for the treatment of diabetes mellitus with promising prospects.